119 related articles for article (PubMed ID: 8183564)
1. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met).
Zhen Z; Giordano S; Longati P; Medico E; Campiglio M; Comoglio PM
Oncogene; 1994 Jun; 9(6):1691-7. PubMed ID: 8183564
[TBL] [Abstract][Full Text] [Related]
2. Autophosphorylation modulates the kinase activity and oncogenic potential of the Met receptor tyrosine kinase.
Rodrigues GA; Park M
Oncogene; 1994 Jul; 9(7):2019-27. PubMed ID: 8208547
[TBL] [Abstract][Full Text] [Related]
3. Identification of tyrosine 489 in the carboxy terminus of the Tpr-Met oncoprotein as a major site of autophosphorylation.
Kamikura DM; Naujokas MA; Park M
Biochemistry; 1996 Jan; 35(3):1010-7. PubMed ID: 8547236
[TBL] [Abstract][Full Text] [Related]
4. Efficient cell transformation by the Tpr-Met oncoprotein is dependent upon tyrosine 489 in the carboxy-terminus.
Fixman ED; Naujokas MA; Rodrigues GA; Moran MF; Park M
Oncogene; 1995 Jan; 10(2):237-49. PubMed ID: 7838524
[TBL] [Abstract][Full Text] [Related]
5. Deletion of the ectodomain unleashes the transforming, invasive, and tumorigenic potential of the MET oncogene.
Merlin S; Pietronave S; Locarno D; Valente G; Follenzi A; Prat M
Cancer Sci; 2009 Apr; 100(4):633-8. PubMed ID: 19175607
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene.
Vigna E; Naldini L; Tamagnone L; Longati P; Bardelli A; Maina F; Ponzetto C; Comoglio PM
Cell Mol Biol (Noisy-le-grand); 1994 Jul; 40(5):597-604. PubMed ID: 7981617
[TBL] [Abstract][Full Text] [Related]
7. Tyrosines1234-1235 are critical for activation of the tyrosine kinase encoded by the MET proto-oncogene (HGF receptor).
Longati P; Bardelli A; Ponzetto C; Naldini L; Comoglio PM
Oncogene; 1994 Jan; 9(1):49-57. PubMed ID: 8302603
[TBL] [Abstract][Full Text] [Related]
8. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
9. Loss of the exon encoding the juxtamembrane domain is essential for the oncogenic activation of TPR-MET.
Vigna E; Gramaglia D; Longati P; Bardelli A; Comoglio PM
Oncogene; 1999 Jul; 18(29):4275-81. PubMed ID: 10435641
[TBL] [Abstract][Full Text] [Related]
10. Mutant Met-mediated transformation is ligand-dependent and can be inhibited by HGF antagonists.
Michieli P; Basilico C; Pennacchietti S; Maffè A; Tamagnone L; Giordano S; Bardelli A; Comoglio PM
Oncogene; 1999 Sep; 18(37):5221-31. PubMed ID: 10498872
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the wild-type and Y1235D mutant Met kinase activation.
Cristiani C; Rusconi L; Perego R; Schiering N; Kalisz HM; Knapp S; Isacchi A
Biochemistry; 2005 Nov; 44(43):14110-9. PubMed ID: 16245927
[TBL] [Abstract][Full Text] [Related]
12. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1.
Bosch E; Cherwinski H; Peterson D; McMahon M
Oncogene; 1997 Aug; 15(9):1021-33. PubMed ID: 9285556
[TBL] [Abstract][Full Text] [Related]
13. Modifications of the hepatocyte growth factor/c-met pathway by constitutive expression of transforming growth factor-alpha in rat liver epithelial cells.
Presnell SC; Stolz DB; Mars WM; Jo M; Michalopoulos GK; Strom SC
Mol Carcinog; 1997 Apr; 18(4):244-55. PubMed ID: 9142219
[TBL] [Abstract][Full Text] [Related]
14. Signaling requirements for oncogenic forms of the Met tyrosine kinase receptor.
Jeffers M; Koochekpour S; Fiscella M; Sathyanarayana BK; Vande Woude GF
Oncogene; 1998 Nov; 17(21):2691-700. PubMed ID: 9840933
[TBL] [Abstract][Full Text] [Related]
15. Activation of pp60c-src transforming potential by mutations altering the structure of an amino terminal domain containing residues 90-95.
Potts WM; Reynolds AB; Lansing TJ; Parsons JT
Oncogene Res; 1988; 3(4):343-55. PubMed ID: 2465527
[TBL] [Abstract][Full Text] [Related]
16. Transformation by oncogenic mutants and ligand-dependent activation of FLT3 wild-type requires the tyrosine residues 589 and 591.
Vempati S; Reindl C; Wolf U; Kern R; Petropoulos K; Naidu VM; Buske C; Hiddemann W; Kohl TM; Spiekermann K
Clin Cancer Res; 2008 Jul; 14(14):4437-45. PubMed ID: 18628457
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic activation of the tyrosine kinase domain of the human trk proto-oncogene by fusion to a cell adhesion molecule.
Albor A; Thraves PJ; Dritschilo A; Notario V
Oncogene; 1996 Oct; 13(8):1755-63. PubMed ID: 8895522
[TBL] [Abstract][Full Text] [Related]
18. Differential requirement of the last C-terminal tail of Met receptor for cell transformation and invasiveness.
Gual P; Giordano S; Anguissola S; Comoglio PM
Oncogene; 2001 Sep; 20(39):5493-502. PubMed ID: 11571647
[TBL] [Abstract][Full Text] [Related]
19. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
20. A juxtamembrane autophosphorylation site in the Eph family receptor tyrosine kinase, Sek, mediates high affinity interaction with p59fyn.
Ellis C; Kasmi F; Ganju P; Walls E; Panayotou G; Reith AD
Oncogene; 1996 Apr; 12(8):1727-36. PubMed ID: 8622893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
